Form 4: Director Bernadette Connaughton Sells Halozyme Shares

Halozyme Therapeutics director Bernadette Connaughton sold 1,625 shares of common stock on June 1, 2026.

Summary

• Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics (HALO) common stock.
• The shares were sold at a price of $66.21 per share.
• Following the transaction, the director retains beneficial ownership of 43,669 shares.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-established, automated trading plan.

Positives

• The sale was conducted via a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in the short-term price appreciation of the stock.

Risks

• Market volatility affecting the share price of Halozyme Therapeutics.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is common in the biotechnology sector and typically does not signal a change in corporate strategy or fundamental health.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the director's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Halozyme Therapeutics, HALO, Insider Trading, Form 4, Biotech, Director Sale